Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$3.13 -1.6%	$2.67	$1.60 ▼ $15.04	$84.74M	1.84	267,378 shs	77,872 shs
NBTX Nanobiotix	$7.96 +7.6%	$5.49	$2.76 ▼ $8.47	$381.79M	0.45	11,318 shs	47,564 shs
RCKT Rocket Pharmaceuticals	$3.09 +6.2%	$2.95	$2.19 ▼ $22.01	$333.42M	0.65	3.36 million shs	3.22 million shs
RNAC Cartesian Therapeutics	$11.71 +3.4%	$11.57	$8.46 ▼ $26.50	$304.48M	0.44	82,728 shs	62,509 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+4.42%	+3.57%	+22.46%	+43.69%	-61.19%
NBTX Nanobiotix	+4.28%	+8.04%	+41.97%	+92.84%	+57.18%
RCKT Rocket Pharmaceuticals	-0.34%	-4.28%	-1.69%	-51.90%	-84.64%
RNAC Cartesian Therapeutics	+2.07%	-4.23%	-14.94%	+13.53%	-10.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	2.0769 of 5 stars	3.3	1.0	0.0	1.7	0.0	1.3
NBTX Nanobiotix	0.6675 of 5 stars	1.3	3.0	0.0	2.7	0.0	0.6
RCKT Rocket Pharmaceuticals	4.8741 of 5 stars	4.2	4.0	4.7	1.7	4.2	1.3
RNAC Cartesian Therapeutics	1.9457 of 5 stars	3.4	0.0	0.0	2.8	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	171.57% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	0.45% Upside
RCKT Rocket Pharmaceuticals	2.35	Hold	$16.33	428.59% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.00	241.59% Upside

Current Analyst Ratings Breakdown

Latest ANRO, NBTX, RNAC, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
7/25/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
7/25/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$9.00 ➝ $4.00
7/24/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $12.00
7/24/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
NBTX Nanobiotix	$39.18M	9.74	N/A	N/A	($1.51) per share	-5.27
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.28 per share	N/A
RNAC Cartesian Therapeutics	$1.03M	296.77	N/A	N/A	($0.10) per share	-117.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.34	N/A	N/A	N/A	N/A	-39.35%	-33.86%	N/A
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.51	N/A	N/A	N/A	N/A	-65.11%	-55.99%	N/A
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-6.36%	N/A

Latest ANRO, NBTX, RNAC, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A
8/7/2025	Q2 2025	RNAC Cartesian Therapeutics	-$0.76	$0.50	+$1.26	$0.50	$0.77 million	$0.30 million
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.15	22.53	22.53
NBTX Nanobiotix	N/A	1.04	1.04
RCKT Rocket Pharmaceuticals	0.05	6.39	9.19
RNAC Cartesian Therapeutics	N/A	13.33	12.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
NBTX Nanobiotix	38.81%
RCKT Rocket Pharmaceuticals	98.39%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	N/A
NBTX Nanobiotix	3.45%
RCKT Rocket Pharmaceuticals	24.76%
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
NBTX Nanobiotix	100	47.94 million	46.29 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	107.90 million	81.19 million	Optionable
RNAC Cartesian Therapeutics	64	26.00 million	10.32 million	Optionable

ANRO, NBTX, RNAC, and RCKT Headlines

Recent News About These Companies

Cartesian (RNAC) Q2 Revenue Drops 99%

August 9, 2025 | theglobeandmail.com

Cartesian Therapeutics Reports Positive Q2 2025 Earnings

August 8, 2025 | tipranks.com

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | taiwannews.com.twT

Cartesian Therapeutics (RNAC) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 4, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?

July 24, 2025 | zacks.com

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

July 9, 2025 | msn.com

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21, 2025 | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 17, 2025 | investing.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.netM

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

Cartesian Therapeutics Announces New Employment Inducement Grants

May 2, 2025 | globenewswire.com

Cartesian Therapeutics management to meet with BTIG

April 26, 2025 | markets.businessinsider.com

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%

April 22, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, NBTX, RNAC, and RCKT Company Descriptions

Alto Neuroscience NYSE:ANRO

$3.13 -0.05 (-1.57%)

Closing price 03:59 PM Eastern

Extended Trading

$3.10 -0.03 (-0.83%)

As of 06:35 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Nanobiotix NASDAQ:NBTX

$7.96 +0.56 (+7.62%)

Closing price 03:58 PM Eastern

Extended Trading

$7.98 +0.02 (+0.20%)

As of 07:58 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.09 +0.18 (+6.19%)

Closing price 04:00 PM Eastern

Extended Trading

$3.10 +0.01 (+0.32%)

As of 07:59 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Cartesian Therapeutics NASDAQ:RNAC

$11.71 +0.38 (+3.35%)

Closing price 04:00 PM Eastern

Extended Trading

$11.77 +0.06 (+0.51%)

As of 04:06 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time